Avanti Polar Lipids, Inc.

Ac Immune Sa

Biomolecular Products, Inc.

Other

Children's Hospital Los Angeles

Signpath Pharma, Inc.

The Scripps Research Institute

University of Pretoria

Walter Allen Shaw

Stephen W Burgess

Shengrong Li

David W Yesair

Robert Travis McKee

David T Hickman

Maria Pilar Lopez-Deber

Lawrence Helson

Barry J Maurer

Charles Patrick Reynolds

Robert Travis Mckee

Travis Mckee

Muhammed Majeed

Annie Bouchard

Charles G Cochrane

Jan Adrianus Verschoor

George M Shopp

C Patrick Reynolds

Stephen Burgess

Carl Baumeister

Peter P Sordillo

Ronald A Simon

Barry James Maurer

Travis Robert Mckee

The present disclosure provides for a composition which may be used for the solubilization of an agent or the oral administration of an agent, the composition comprising, a lysophosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lysophosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lysophosphatidyl compound, a monoglyceride and a free fatty acid.

Oral composition for delivery of drugs and other substances

The invention provides compositions and methods for disrupting preformed bacterial biofilm or preventing formation of bacterial biofilm. Also provided in the invention are methods and compositions for treating and preventing chronic rhinosinusitis. Such compositions and methods utilize one or more antibiotic compounds in combination with at least one phospholipid compound described herein.

Therapies for treating and preventing chronic rhinosinusitis

The present invention includes methods and compositions for ameliorating symptoms or treating one or more adverse reactions triggered by infectious diseases or disease conditions that trigger a widespread release of cytokines in a subject comprising the steps of: identifying the subject in need of amelioration of symptoms or treatment of the infectious diseases or disease conditions that trigger a widespread release of cytokines; and administering one or more pharmaceutical compositions comprising a therapeutically effective amount of a curcumin extract, curcuminoids or synthetic curcumin (S-curcumin) and derivatives thereof, or empty liposomes, dissolved or dispersed in a suitable aqueous or non-aqueous medium sufficient to reduce the level of cytokines in the host.

Suppression of cytokine release and cytokine storm

The present disclosure provides for a composition which may be used for the solublization of an agent or the oral administration of an agent, the composition comprising, a lyosphosphatidyl compound and at least one of a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises a lyosphosphatidyl compound, a monoglyceride and a free fatty acid. In certain embodiments, the composition comprises an agent, a lyosphosphatidyl compound, a monoglyceride and a free fatty acid.

The present invention includes compositions and methods for preventing one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by an active agent or a drug in a human or animal subject comprising: an amount of a lysophosphatidyl compound adapted for oral administration effective to reduce or prevent one or more cardiac channelopathies or conditions resulting from irregularities or alterations in cardiac patterns caused by the active agent or drug. Such compositions may further comprise a monoglyceride, a free fatty acid or a combination of the foregoing, including, e.g., a eutectic mixture.

Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies

A liposomal composition comprising a sterol-modified lipid and a purified mycobacterial lipid cell wall component or analog or derivative thereof is described. The composition is useful as a lipid antigen-presenting vehicle for the detection of lipid antigen specific biomarker antibodies in antibody containing biological samples in the diagnosis of active tuberculosis. The purified lipid cell wall component is typically a purified mycolic acid or a mixture of mycolic acids from athat produces mycolic acids. The sterol-modified lipid is typically a phospholipid.

Liposomal composition comprising a sterol-modified lipid and a purified mycobacterial lipid cell wall component and its use in the diagnosis of tuberculosis

Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.

Disaccharide synthetic lipid compounds and uses thereof

Essentially pure compounds of the formulas (I) to (XXV) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources.

Disclosed are compounds of the general formula I and II (as further defined herein) are useful in the production of inhibitors of sphingolipid synthesis the production of sphingolipids. Suitable sphingolipids, include, but not limited to, sphingosine and compounds incorporating sphingosine or that may use sphingosine as an intermediate or a starting material in their synthesis (including, but not limited to, sphingosine-1-P, ceramide, gangliosides and sphingomyelin). In one contemplated use, compounds of the general formula I and II are useful in the production of sphingosine. In another contemplated use, compounds of the general formula I and II are useful in the production of a sphingofugin. Methods of manufacturing each of the above compounds are also provided.

Compounds

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase Aare provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

Modifications of solid 3-sn-phosphoglycerides

The present invention provides an edible composition for oral delivery of an active agent such as a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

Oral compositions of fenretinide having increased bioavailability and methods of using the same

The present invention provides an edible composition for oral delivery of an active agent such as paclitaxel or a retinide. The composition comprises, in the form of a dry flowable powder: (a) an active agent such as a retinide; (b) lipid matrix composition; (c) optionally sweetener; (d) flour. Compositions of the invention may be administered per se or mixed with a solid or liquid food carrier, for direct oral consumption by a subject or administration through a feeding tube.

Growing community of inventors

Birmingham, AL, United States of America

Walter Allen Shaw